GTSM:6492

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company, identifies and develops therapies for the treatment of cancer. More Details


Snowflake Analysis

Exceptional growth potential with adequate balance sheet.

Share Price & News

How has Senhwa Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6492 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 6492's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

8.4%

6492

-0.3%

TW Biotechs

2.0%

TW Market


1 Year Return

184.4%

6492

22.9%

TW Biotechs

31.2%

TW Market

Return vs Industry: 6492 exceeded the TW Biotechs industry which returned 22.9% over the past year.

Return vs Market: 6492 exceeded the TW Market which returned 31.2% over the past year.


Shareholder returns

6492IndustryMarket
7 Day8.4%-0.3%2.0%
30 Day-18.2%-6.1%10.6%
90 Day-22.1%-0.3%22.8%
1 Year184.4%184.4%23.3%22.9%35.8%31.2%
3 Year156.8%156.8%-18.1%-19.5%58.3%40.5%
5 Year28.3%28.3%-51.3%-51.7%133.0%92.1%

Long-Term Price Volatility Vs. Market

How volatile is Senhwa Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Senhwa Biosciences undervalued compared to its fair value and its price relative to the market?

6.7x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 6492 (NT$190.5) is trading above our estimate of fair value (NT$140.49)

Significantly Below Fair Value: 6492 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 6492 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6492 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6492's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6492 is overvalued based on its PB Ratio (7.1x) compared to the TW Biotechs industry average (4.8x).


Next Steps

Future Growth

How is Senhwa Biosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

107.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6492 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).

Earnings vs Market: 6492 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 6492's is expected to become profitable in the next 3 years.

Revenue vs Market: 6492's revenue (110% per year) is forecast to grow faster than the TW market (11.2% per year).

High Growth Revenue: 6492's revenue (110% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6492's Return on Equity is forecast to be high in 3 years time (30.9%)


Next Steps

Past Performance

How has Senhwa Biosciences performed over the past 5 years?

-13.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6492 is currently unprofitable.

Growing Profit Margin: 6492 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6492 is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.

Accelerating Growth: Unable to compare 6492's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6492 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).


Return on Equity

High ROE: 6492 has a negative Return on Equity (-14.63%), as it is currently unprofitable.


Next Steps

Financial Health

How is Senhwa Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: 6492's short term assets (NT$2.5B) exceed its short term liabilities (NT$76.5M).

Long Term Liabilities: 6492's short term assets (NT$2.5B) exceed its long term liabilities (NT$3.7M).


Debt to Equity History and Analysis

Debt Level: 6492's debt to equity ratio (0.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 6492's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6492 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 6492 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Senhwa Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6492's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6492's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6492's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6492's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6492's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average board tenure


CEO

Tai-Sen Soong

no data

Tenure

NT$14,717,000

Compensation

Dr. Tai-Sen Soong, Ph.D. is a Co-Founder of Medtech Tronics, Inc. Dr. Soong serves as the President and Vice Chairman at CDIB BioScience Venture Management. Dr. Soong serves as Chief Executive Officer at S...


CEO Compensation Analysis

Compensation vs Market: Tai-Sen's total compensation ($USD525.38K) is about average for companies of similar size in the TW market ($USD442.53K).

Compensation vs Earnings: Insufficient data to compare Tai-Sen's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
Tai-Sen Soong
CEO, President & Directorno dataNT$14.72mno data
Ting-Wu Hu
Chairmanno datano datano data
Chia-Hung Lee
Supervisor5.83yrsno datano data
Hung-Ming Hsieh
Director8.17yrsno datano data
Chi-Hai Lin
Supervisor4.58yrsno datano data
Kuo-Shiang Lee
Independent Director5.83yrsNT$60.00kno data
Kwei-Hang Chan
Director8.17yrsNT$60.00kno data
Jien-Fu Chen
Director3.58yrsno datano data
Yeu-Chuyr Chang
Independent Director5.83yrsNT$80.00kno data
Eric Hu
Supervisor3.58yrsno datano data

5.8yrs

Average Tenure

Experienced Board: 6492's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.3%.


Top Shareholders

Company Information

Senhwa Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Senhwa Biosciences, Inc.
  • Ticker: 6492
  • Exchange: GTSM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$16.131b
  • Shares outstanding: 89.62m
  • Website: https://www.senhwabio.com

Location

  • Senhwa Biosciences, Inc.
  • No. 225, Peihsin Road
  • 10th Floor
  • New Taipei City
  • 23143
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6492GTSM (Taipei Exchange)YesCommon SharesTWTWDDec 2014

Biography

Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company, identifies and develops therapies for the treatment of cancer. The company is developing CX-4945 that is in phase I/II clinical trial i...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/26 17:28
End of Day Share Price2021/01/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.